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ABSTRACT Phagocytic cells are widely distributed in tis-
sues known to be important in the metabolism of vitamin 1D,
Incubation of human pqlymorphonuclear leukocytes and
monocytes and resident rat peritoneal macrophages with 3H-
labeled 25-hydroxyvitamin D3 leads to the formation of three
radioactive peaks. Peak I is most consistent with a lactone de-
rivative of 25-hydroxyvitamin D3, and peak II has been identi-
fied as putative 24,25-dihydroxyvitamin D3. Peak III is a novel
metabolite of 25-hydroxyvitamin D3 unlike any of the synthetic
standards available in our laboratories. Human neutrophils
converted more substrate than did the other phagocytes exam-
ined. The stimulation of neutrophils by opsonized zymosan or
phorbol myristate acetate led to a 4-fold increase in synthesis
of the metabolites. These results suggest that vitamin D metab-
olism by phagocytic cells may play a role in the microenviron-
mental events that surround bony metabolism and calcium ho-
meostasis.
The microbicidal ability of phagocytic cells and the metabol-
ic events associated with this function have been studied ex-
tensively (1). By comparison, little is known about the in-
volvement of phagocytic cells in endocrine processes.
Phagocytosing neutrophils degrade thyroid hormones in vi-
tro (2). Estradiol is bound to and metabolized by neutrophils
(3). It has been postulated that the increased bactericidal ac-
tivity of neutrophils harvested during pregnancy may be due
to estrogen-mediated enhancement of the myeloperoxidase-
dependent oxidative killing (4). There may also be a relation-
ship between phagocytes and skeletal metabolism. Mono-
cytes resorb bone in vitro (5, 6). Cytosolic receptors for 1,25-
dihydroxyvitamin D3 [1,25-(OH)2D3], an active metabolite of
vitamin D, have been demonstrated recently in human blood
mononuclear cells (7, 8). Monocytes also demonstrate en-
hanced function when incubated with parathyroid hormone
or calcitonin (9). Accordingly, we explored the interaction
between vitamin D and phagocytic cells. We now report that
several phagocytic cells metabolize 25-hydroxyvitamin D3
[25-(OH)D3] in vitro and that these metabolic pathways are
enhanced by stimuli known to increase the microbicidal ac-
tivity of phagocytic cells.
MATERIALS AND METHODS
Materials. 25-Hydroxy[26,27-3H]vitamin D3 {25-
(OH)[3H]D3, specific activity of 19 Ci/mmol; 1 Ci = 37 GBq}
was purchased from Amersham. Media, Hepes, Hanks' bal-
anced salt solution (HBSS), and antibiotics were obtained
from the Tissue Culture Facility of the Cancer Research
Center at the University of North Carolina. The synthetic
metabolities of vitamin D3 were generously donated by M.
Uskokovic of Hoffmann-La Roche (Nutley, NJ). HPLC sol-
vents were purchased as HPLC-grade reagents from Fi-
scher.
Preparation of Neutrophils. Neutrophils were obtained
from normal donors in accordance with the guidelines of the
Human Research Committee of the University of North Car-
olina. Thirty milliliters of whole blood was drawn into a hep-
arinized syringe', and Plasmagel (Roger Bellon, Neuilly,
Prance) was added in a 3:1 ratio for 45 min at 25TC. The
leukocyte-rich supernatent was removed, suspended in
phosphate-buffered saline, and placed above a layer of Fi-
coll/Hypaque. The mixture was centrifuged at 200 x g for 35
min to allow formation of a leukocyte pellet. Contaminating
erythrocytes were lysed with H20 and 3.6% saline. Neutro-
phils were suspended in HBSS and maintained on ice until
usage. Examination of Giemsa-stained specimens showed
that S95% of the cells were neutrophifs.
Preparation of Mononuclear Phagocytes. Mononuclear
phagocytes were obtained by Ficoll/Hypaque separation as
described above. The monocyte-rich layer was washed at
400 x g for 10 min twice in modified HBSS. The final cell
pellet was suspended in Dulbecco's modified Eagle's medi-
um containing L-glutamine, 1% serum, streptomycin (100
jug/ml), and penicillin (100 units/ml). Monocytes were
counted on preparations stained by the Diff-quik method
(Harleco, American Hospital Supply, Philadelphia). Mono-
cytes at 1 x 106 per well were plated in 24-well Falcon plates
for 2 hr at 370C in 5% C02/95% air with high humidity. Cells
were then gently washed three times with HBSS to remove
contaminating lymphocytes. Cells with nonspecific esterase
staining and appropriate morphology were identified as
monocytes, which represented >90% of this population.
Preparation of Resident Peritoneal Macrophages. Resident
peritoneal macrophages were harvested by lavage from vita-
min D-deprived and vitamin D-replete Sprague-Dawley rats
as described (10). All phagocytic cells used were >95% via-
ble based on their ability to exclude -trypan blue dye.
Preparation of Stimuli. Phorbol 12-myristate 13-acetate
(PMA) was obtained from Consolidated Midland (Brewster,
NY) and diluted in dimethyl sulfoxide to 1 mg/ml. Stock
preparations were further diluted in dimethyl sulfoxide be-
fpre usage to allow addition of a final concentration of 100
ng/ml; the final concentration of dimethyl sulfoxide added to
cell preparations was less than 1% (vol/vol). A fresh prepa-
ration of opsonized zymosan was made each day by incubat-
ing 25 mg of zymosan (Sigma) in 0.5 ml of HBSS and 10%
normal serum. After 30 min at 370C, particles were washed
twice by centrifugation. Zymosan was incubated with neu-
trophils at a 10:1 particle/cell ratio.
Metabolism of Vitamin D. In order to examine neutrophil,
monocyte, and macrophage metabolism of vitamin D, 25-
(OH)[3H]D3 or 1,25-(OH)23H]D3 was added to a suspension
or adherent preparation (monocytes) of 106 cells with vari-
ous specific activities. Cells were agitated either in tumbling
Abbreviations: 25-(OH)D3, 25-hydroxyvitamin D3; 25-(OH)[3H]D3,
25-hydroxy[26,27-3H]vitamin D3; (24R)-24,25-(OH)2D3, (24R)-
24,25-dihydroxyvitamin D3; 1,25-(OH)2D3, 1,25-dihydroxyvitamin
D3; PMA, phorbol 12-myristate 13-acetate; PMN(s), polymorphonu-
clear neutrophil(s).
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tubes (polymorphonuclear leukocytes; PMNs) or by lateral
motion (monocytes and macrophages) for 30-120 min at
370C. In some experiments PMA or opsonized zymosan
were added to trigger phagocyte microbicidal metabolism.
Reactions were terminated by the addition of methylene
chloride/methanol, 2:1 (vol/vol), which extracted the lipids
during a 60-min period of gentle agitation. This mixture was
centrifuged, resulting in a phase separation. The organic lay-
er was retained, dried under N2 gas, and redissolved in hex-
ane/n-propanol, 9:1 (vol/vol). The organic extract was ap-
plied to a TLC system using chloroform/ethyl acetate, 1:1
(vol/vol), as described (11). The metabolites formed in vitro
from 25-(OH)D3 were serially chromatographed over three
HPLC systems. The HPLC systems used a Laboratory Data
Control (Riviera Beach, FL) Gradient Master and a microsil-
ica column (Zorbax-Sil, 4 mm x 25 cm, DuPont). The sol-
vent systems included methylene chloride/n-propanol, 95:5
(vol/vol), methylene chloride/methanol, 98:2 (vol/vol), and
hexane/n-propanol at 0.5 ml/min flow rate. Putative identity
of a metabolite was based on the comigration of a radioactive
peak with synthetic standards in at least two different HPLC
systems. The fractions eluted from this system were collect-
ed at 0.5-min intervals, dried, and redissolved in scintillation
cocktail for assay. Radioactivity comigrating with (24R)-
24,25-dihydroxyvitamin D3 [(24R)-24,25-(OH)2D3] was incu-
bated overnight with periodic acid as described (12). The
amount of each metabolite was calculated by correcting the
radioactivity in each peak for recovery, converting corrected
radioactivity to weight by using known specific activity, and
expressing the in vitro formation as nmol per 106 cells per
unit time.
Superoxide Determination. In some experiments the con-
centration of superoxide released by cells stimulated with
PMA and zymosan was used as a positive control to indicate
that vitamin D did not have an adverse effect on cellular met-
abolic function. Superoxide was determined by the reduc-
tion of cytochrome c as described (13). Cell preparations
were incubated with fresh cytochrome c (Sigma, heart cyto-
chrome c type VI) for 30-60 min, and the concentration
formed was determined based on the change in optical densi-
ty.
RESULTS
Resting human PMNs and monocytes and resident rat peri-
toneal cells metabolized 25-(OH)[3H]D3 in vitro to three
radioactive peaks. Fig. 1 shows the elution pattern of the
radioactivity after serial TLC and HPLC of the extracted
cells and medium. Peak I comigrated on two HPLC systems
with authentic 25-(OH)D3-26,23-lactone. Peak II comigrated
on two HPLC systems with authentic (24R)-24,25-(OH)2D3
and was sensitive to periodate cleavage. Peak III comigrated
on one straight-phase HPLC system (microsilica column us-
ing hexane/n-propanol) with authentic 1,25-(OH)2D3. On
two other HPLC systems, peak III did not comnigrate with
1,25-(OH)2D3 or any of the other authentic metabolites avail-
able in this laboratory. Peak III was resistant to periodate
cleavage.
In general, resting phagocytic cells converted only a small
percentage of the 25-(OH)[3H]D3 in vitro. Human monocytes
(n = 3) and rat peritoneal cells (n = 5) converted =1% of the
substrate during the incubation interval. Human PMNs (n =
3) converted 2.8% of the substrate during the same interval.
In the absence of cells, no metabolism of vitamin D was ob-
served. The percentage of substrate conversion remained
constant as the substrate concentration increased as shown
in Fig. 2 for human PMNs and as previously reported for
peak III synthesis by rat peritoneal cells (10). The presence
of serum in the incubation medium (1-5%) or the addition of
1,25-(OH)2D3 to the medium 12 hr prior to the experiment
did not alter the formation of these peaks. Metabolism of
Eb





FIG. 1. The elution pattern of radioactivity obtained after TLC
and HPLC of the PMNs and medium. Elution position of synthetic
metabolites of vitamin D3 is indicated by vertical peaks and labels;
95% of the incubated radioactivity migrated on TLC with 25-
(OH)D3. The other 5% was extracted from the silica into ethyl ace-
tate, dried under N2 gas, and redissolved for injection into the
HPLC system. This elution pattern is from an HPLC system with
methylene chloride/n-propanol, 95:5 (vol/vol) and a Zorbax-Sil col-
umn (4.6 mm x 25 cm). Flow rate was 0.5 ml/min. Elution fractions
were dried and redissolved in scintillation cocktail. The radioactiv-
ity was counted in a Beckman LS-2000 liquid scintillation counter.
vitamin D was substrate specific; in vitro incubation of 1,25-
(OH)2A3H]D3 with rat macrophages under identical conditions
failed to reveal any detectable conversion of this substrate.
Phagocytic cells engage in unique metabolic responses
that enable these cells to provide microbicidal and tumorici-
dal defense (1). These responses can be stimulated by parti-
cle ingestion and a variety of soluble "trigger agents." In or-
der to determine the effects of these responses on the phago-
cytic metabolism of 25-(OH)[3H]D3, human PMNs were
coincubated with 25-(OH)[3H]D3 and opsonized zymosan, a
phagocytic stimulus, or PMA, a soluble stimulus. As expect-
ed, these stimuli lead to the formation and release of super-
oxide ion in significant amounts (Fig. 2). Superoxide ion is
one of the oxygen reduction products formed by phagocytic
cells. As shown in Fig. 2 Lower, a 4-fold increment in the in
vitro formation of putative (24R)-24,25-(OH)2D3 and peak III
was observed. An increment in peak I equal to that observed
for peak III in each experiment was also observed (data not
shown). When vitamin D-deficient rat peritoneal macro-
phages (10) were used, peaks I and III were formed in nor-
mal amounts, whereas the metabolite of peak II was not de-
tected.
DISCUSSION
Resting human PMNs and monocytes and rat peritoneal cells
metabolized 25-(OH)[3H]D3 in vitro to three radioactive
peaks whose chemical identity and biological activity are un-
der investigation. The metabolism of vitamin D by phagocyt-
ic cells is a phenomenon whose significance is presently un-
known. However, phagocytic cells are anatomically ubiqui-
tous and exist in organs known to metabolize vitamin D,
including the kidneys (14), the liver (15), bone (16), and the
placenta (17, 18). Phagocytic cells are found also in models
Proc. NatL Acad Sci. USA 81 (1984)
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FIG. 2. (Upper) In vitro formation of two metabolites of 25-
(OH)D3 designated 24,25-(OH)2D3 (peak II) and metabolite III (peak
III). PMNs were incubated with 25-(OH)[3H]D3 at four time inter-
vals and two different substrate concentrations. (Typical of three
experiments.) (Lower) In vitro formation of vitamin D metabolites
and superoxide ion when PMNs were incubated in the presence of
PMA (30 min) or opsonized zymosan (60 min). These results are
typical of two experiments performed in duplicate.
of bone formation (19). Hence, an understanding of phago-
cytic metabolism of vitamin D is an important topic.
The yield of the radioactive peaks formed by phagocytes
metabolizing 1,25-(OH)2D3 was low, ranging from 1% for
resting monocytes and peritoneal cells to 2.8% for the
PMNs. A low yield of reaction products is not peculiar to
phagocytic cells. Mammalian renal cells handled under simi-
lar conditions yielded small quantities of reaction products
(20, 21). The low yield associated with the in vitro examina-
tion of mammalian cells has been attributed to the trauma of
isolation, limited solubility of substrate in medium, and limit-
ed accessibility of the substrate to the subcellular reaction
site (20, 21). The present findings show that the stimulation
of human PMNs by zymosan particles or PMA leads to a 4-
fold increase in vitamin D metabolites. This increment dem-
onstrated that vitamin D metabolism by resting PMNs was
responsive to agents known to stimulate the microbicidal ac-
tivity of phagocytic cells despite the limitations of our ex-
perimental methods.
At present only putative identities can be assigned to the
three radioactive peaks observed on the chromatograms
(Fig. 1). Peak I comigrated on two HPLC systems with the
lactone derivative of 25-(OH)D3. Peak II is putative (24R)-
24,25-(OH)2D3 for three reasons. First, it comigrated with
authentic (24R)-24,25-(OH)2D3 on two different HPLC sys-
tems. Second, it was sensitive to periodate cleavage. Third,
it was not present when peritoneal cells from vitamin D-de-
prived rats were studied, which is consistent with induction
of 24-hydroxylase activity by exposure to vitamin D (22).
Peak III is interesting because it appears to be a novel me-
tabolite that might be mistaken for 1,25-(OH)2D3 unless rig-
orous chromatographic procedures are performed (10). Peak
III has been recognized previously as a metabolite of 25-
(OH)D3 formed in vitro by rodent macrophages (10). Peak III
has a unique chromatographic profile and crossreacted in a
radioimmunoassay for 1,25-(OH)2D3 developed in this labo-
ratory (23). It was also resistant to periodate cleavage. Thus,
peak III is not similar to any known metabolites of 25-
(OH)D3, and its identification must await the outcome of
mass spectroscopy and chemical analysis.
Several features ofthe phagocyte metabolism of25-(OH)D3
merit additional comment. The three peaks formed in vitro
by phagocytic cells were produced in equal amounts in all
experiments except those involving cells from vitamin D-de-
ficient animals. No temporal sequence in the formation of
these metabolites was observed. Except in the case of vita-
min D-deficient rats, whenever one peak was present, all
three peaks were detected. However, the ability to synthe-
size these metabolites varied according to cell type. Resting
PMNs were more metabolically active than monocytes and
peritoneal cells. These findings provide no evidence for a
biologic effect of any of the metabolites. The observed meta-
bolic pathway may be degradative or important in synthesis
of substances with unique properties. It is interesting to
speculate that one or more of the metabolites may belong to
the oxo-derivatives of 25-(OH)D3, a newly recognized group
of metabolites (24). Of further interest is the fact that 1,25-
dihydroxy-24-oxovitamin D3 possesses bioactivity in a bone
resorption assay (25).
Other facts linking phagocytic cells and vitamin D have
been reported. Vitamin D deficiency in laboratory mice is
associated with a blunted inflammatory response (26). Mice
deprived of vitamin D during uterine development demon-
strate a persistent reduction in their ability to form splenic
colony-forming units (27). Cytosolic receptors for 1,25-
(OH)2D3 have been demonstrated recently in human blood
mononuclear cells (7, 8). Several cell lines with marrow stem
cell properties have been induced to differentiate into macro-
phage-like cells by incubation with 1,25-(OH)2D3, (24R)-
24,25-(OH)2D3, or 25-(OH)D3 (28-30). Recently, the micro-
environmental events surrounding bone metabolism have
been the subject of intense scrutiny, as has the involvement
of phagocytic cells (or phagocyte-derived cells) in these
processes. The biological implication of the formation of vi-
tamin D metabolites by phagocytes warrants further study.
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